top of page
Browse by category
Search
UK biobank study reveals link between new-onset T2DM and some, but not all, obesity-related cancers
Research to be presented at this year’s European Congress on Obesity 2025 (Malaga, Spain) shows that a new diagnosis of type 2 diabetes...
GLP-1 drugs benefit children who are living with severe obesity
Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs...
16.7% average weight loss on GLP-1 micro-dosing of 1.08 mg semaglutide per week
In one of the largest and longest real-world obesity studies to date that tracked nearly 2,700 adults over 64 weeks found patients...
Proportion of adolescents living with overweight and obesity in England increased by 50% between 2008 and 2023
The proportion of adolescents living with overweight or obesity in England has increased by 50% from 2008-2010 (22%) to 2021-2023 (33%),...
Targeting percentage weight loss targets is the wrong objective
Weight loss programmes targeting a particular percentage of weight loss are often failing, and that other factors should be considered...
GLP-s are safe and effective for treating obesity in adults with mental illness
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with...
Women more likely to be aware of and have good understanding of obesity drugs
Women are much more aware of and knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and...
GLP-1ras show anti-cancer benefits beyond weight loss
First generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss. Indeed,...
Global survey reveals high disconnect between perceptions of obesity among patient and healthcare professionals
A survey of adults living with obesity and their physicians across seven countries reveals a high disconnect between their perceptions...
Browse by tag
bottom of page